Developer docs
API playgroundTry for free, no card

Search company profiles

Bebig

Full company profile

uuid000u4fu

Namestring
Bebig
Legal namestring
ООО «БЕБИГ»
Websiteurl
bebig.ru
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Bebig is a Russian medical technology company headquartered in Moscow that specializes in the preparation and packaging of radioactive sources for brachytherapy and adjacent radiation oncology applications. The business is structured as a private Russian limited liability company (ООО «БЕБИГ») operating from a single Moscow office with a workforce of 11–50 employees. The company's remit spans the full brachytherapy continuum—from low-dose prostate cancer treatment to high-dose, image-guided, and intraoperative radiation therapy across multiple tumor types.

The product portfolio covers seven core platforms. For low-dose brachytherapy, Bebig produces I-125 microseeds used in minimally invasive prostate cancer treatment. For liver cancer, Bebig manufactures Y-90 microspheres used in radioembolization, claiming to be the first Russian domestic producer in this category and positioning the product as nuclear medicine import substitution. For high-dose brachytherapy, the Multisource and SagiNova systems deliver remote high-dose-rate radiation using Co-60 and Ir-192 isotopes, paired with the SagiPlan dosimetry planning software. The portfolio also includes a targeted fusion biopsy system (MRI–ultrasound image registration for prostate diagnostics), Ru-106 ophthalmological applicators for eye tumors, the Womed device for superficial and intraoperative radiation therapy, and the Biobeam blood, blood-component, tissue, and organ irradiation system.

The business model is a hybrid equipment, consumable, and services model sold via direct enterprise field sales to Russian oncology hospitals and cancer centers. Revenue is generated through capital equipment sales (Multisource, SagiNova, fusion biopsy, Biobeam, Womed), recurring consumables (I-125 microseeds, Y-90 microspheres, Ru-106 applicators), and service/maintenance plus physician training contracts. Critically, Bebig's low-dose brachytherapy treatment has been included in the Russian state High-Tech Medical Care (VMP) program, meaning treatments using the technology are government-funded for Russian citizens. Named partners and customers are concentrated in Russian state and academic oncology institutions (Blokhin NMIC, NMIC Radiology, Hospital No. 122, Sevastopol Oncology Center, Tyumen State Medical University), with one international reference site in Bratislava, Slovakia. The company is ISO 13485:2016 certified and reports no public listing, ticker, or institutional investor disclosures.

Short descriptiontext

Bebig is a Russian medical technology company that manufactures radioactive sources and brachytherapy systems—including I-125 prostate microseeds, Y-90 liver microspheres, high-dose Co-60/Ir-192 delivery systems, and related planning software—sold to state oncology hospitals and cancer centers, with treatments partially covered by Russian state High-Tech Medical Care programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMoscow, Russia
HQ citystring
Moscow
HQ countrystring
Russia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brachytherapy medical devices, radiation oncology systems, prostate cancer treatment, liver cancer radioembolization, medical isotope products
Industry3 codes
PRIMARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAKAFAC
Radiation Oncology
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
  • Surgical & Medical Instruments & Apparatus3841
Product category
Radiation Oncology and Brachytherapy Systems
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical devices and equipment
TypeHardware Sales
Description

Sale and service of brachytherapy equipment including Multisource and SagiNova high-dose therapy systems, planning software (SagiPlan), and Womed intraoperative radiation therapy devices

bebig.ru
2Consumables and microseeds
TypeHardware Sales
Description

I-125 microseeds for low-dose brachytherapy, Y-90 microspheres for liver cancer treatment, and Ru-106 ophthalmological applicators

bebig.ru
3Service and training
TypeProfessional Services
Description

Service maintenance for therapy equipment, physician training programs in Russia and abroad, and organization of brachytherapy treatment rooms in clinics

bebig.ru
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1SagiNova
Description

High-dose brachytherapy system for remote introduction of high-dose radioactive preparations

bebig.ru
+4 more records
Core offering1 text field

Bebig develops, manufactures, and supplies brachytherapy and radiation oncology products for cancer treatment. The portfolio includes I-125 low-dose microseeds for prostate cancer brachytherapy, Y-90 microspheres for liver cancer radioembolization, Multisource and SagiNova high-dose brachytherapy systems using Co-60 and Ir-192 isotopes, SagiPlan dosimetry software, MRI/ultrasound fusion biopsy systems, Ru-106 ophthalmic applicators, Womed intraoperative radiation therapy devices, and Biobeam blood irradiation systems, complemented by service maintenance, physician training, and brachytherapy room organization services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10-year survival rate averages 87% according to various studies
+2 more records
Product overview1 text field

Bebig is a Russian medical technology company specializing in advanced brachytherapy and radiation oncology products. The company's portfolio includes low-dose rate brachytherapy micro-sources (I-125) for prostate cancer treatment, Y-90 microspheres for radioembolization of liver tumors, high-dose rate brachytherapy systems (Multisource, SagiNova, SagiPlan) using Co-60 and Ir-192 isotopes, fusion biopsy systems for prostate cancer diagnosis, Ru-106 ophthalmic applicators, Womed devices for intraoperative radiation therapy, and Biobeam blood irradiation systems. The company operates as a unified product portfolio focused on nuclear medicine and radiation oncology solutions for cancer treatment across multiple treatment areas including prostate cancer, liver cancer, and eye tumors.

Product and service1 record
1I-125 Microseeds for Low-Dose Brachytherapy
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Sevastopol Oncology Center
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Recently began performing radioembolization of liver tumors using Bebig-produced Y-90 microspheres as of May 2026.

bebig.ru
2FSBI NMITs Oncology named after N.N. Blokhin of the Ministry of Health of Russia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major national oncology center collaborating with Bebig on brachytherapy treatments. The center's deputy director for development of oncological care in regions serves as an expert advocate for brachytherapy as an innovative method combining advanced technologies with excellent results and minimally invasive techniques.

bebig.ru
3FSBI NMIC Radiology of the Ministry of Health of Russia
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading national radiology center under the Ministry of Health, headed by the Chief внештатный oncologist of Russia. The center collaborates with Bebig as an example of quality and reliable import substitution, particularly in radiofarm production with Russian Y-90 microspheres.

bebig.ru
4FMBU Clinical Hospital No. 122 named after L.G. Sokolov
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading brachytherapy center performing prostate cancer treatments. The hospital's Prostate Cancer Brachytherapy Center, led by a Prize laureate of the St. Petersburg Government, uses Bebig technology exclusively.

bebig.ru
5Tyumen State Medical University Oncology Department
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic institution conducting research on brachytherapy effectiveness, with studies reporting 87% 10-year survival rates.

bebig.ru
Strategic tierMinorTypeStrategic or Co-development Partner
Description

International reference center using Bebig technology, with published studies confirming brachytherapy effectiveness for prostate cancer across risk groups.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston Scientific's TheraSphere Y-90 glass microspheres compete head-to-head with Bebig's Y-90 product for liver cancer radioembolization procedures across major cancer centers.

TypeDirect peer
Description

Varian offers the GammaMed, VariSource, and Bravos HDR brachytherapy afterloaders and the BrachyVision planning system, directly competing with Bebig's high-dose brachytherapy portfolio in hospitals globally.

TypeRegional player
Description

The Chinese BEBIG Medical entity sells Eckert & Ziegler-derived brachytherapy products (HDR afterloaders, seeds) into the Chinese and Asian markets - same product lineage as the systems Bebig (Russia) distributes, but serving a different geography without direct overlap.

TypeDirect peer
Description

IsoRay manufactures Cesium-131 and I-125 brachytherapy seeds for prostate and other cancers - directly comparable isotope-based seed product category to Bebig's I-125 microseeds.

5Nordion (Sotera Health)
TypeDirect peer
Description

Nordion supplies medical isotopes including Co-60 and I-125 used in brachytherapy devices and sterilization - a key input supplier and indirect competitor to Bebig's vertically integrated isotope production.

TypeDirect peer
Description

Theragenics produces brachytherapy seeds (I-125, Pd-103) and operates the Galt Medical and surgical products businesses, overlapping directly with Bebig's brachytherapy seed and applicator portfolio.

TypeEmerging player
Description

Mevion develops compact proton therapy systems as an alternative radiation oncology modality; not a direct brachytherapy peer but competes for radiation oncology capital budgets at the same hospitals Bebig sells into.

TypeDirect peer
Description

Eckert & Ziegler acquired the original German BEBIG and produces HDR brachytherapy afterloaders (Multisource, SagiNova) and I-125 seeds that Bebig (Russia) distributes alongside its own microsphere production. Directly comparable product portfolio and isotope-based technology.

TypeDirect peer
Description

Sirtex manufactures SIR-Spheres Y-90 resin microspheres for liver radioembolization - the global benchmark for the product that Bebig is producing domestically in Russia. Closest direct competitor in the Y-90 microsphere category.

TypeDirect peer
Description

Elekta is the global leader in HDR brachytherapy afterloaders (Flexitron), treatment planning software, and applicators - directly competing with Bebig's Multisource/SagiNova systems and SagiPlan planning software in radiation oncology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bebig

Radiation Oncology and Brachytherapy Systemsbebig.ru

Bebig is a Russian medical technology company that manufactures radioactive sources and brachytherapy systems—including I-125 prostate microseeds, Y-90 liver microspheres, high-dose Co-60/Ir-192 delivery systems, and related planning software—sold to state oncology hospitals and cancer centers, with treatments partially covered by Russian state High-Tech Medical Care programs.

What Bebig does

Bebig is a Russian medical technology company headquartered in Moscow that specializes in the preparation and packaging of radioactive sources for brachytherapy and adjacent radiation oncology applications. The business is structured as a private Russian limited liability company (ООО «БЕБИГ») operating from a single Moscow office with a workforce of 11–50 employees. The company's remit spans the full brachytherapy continuum—from low-dose prostate cancer treatment to high-dose, image-guided, and intraoperative radiation therapy across multiple tumor types.

The product portfolio covers seven core platforms. For low-dose brachytherapy, Bebig produces I-125 microseeds used in minimally invasive prostate cancer treatment. For liver cancer, Bebig manufactures Y-90 microspheres used in radioembolization, claiming to be the first Russian domestic producer in this category and positioning the product as nuclear medicine import substitution. For high-dose brachytherapy, the Multisource and SagiNova systems deliver remote high-dose-rate radiation using Co-60 and Ir-192 isotopes, paired with the SagiPlan dosimetry planning software. The portfolio also includes a targeted fusion biopsy system (MRI–ultrasound image registration for prostate diagnostics), Ru-106 ophthalmological applicators for eye tumors, the Womed device for superficial and intraoperative radiation therapy, and the Biobeam blood, blood-component, tissue, and organ irradiation system.

The business model is a hybrid equipment, consumable, and services model sold via direct enterprise field sales to Russian oncology hospitals and cancer centers. Revenue is generated through capital equipment sales (Multisource, SagiNova, fusion biopsy, Biobeam, Womed), recurring consumables (I-125 microseeds, Y-90 microspheres, Ru-106 applicators), and service/maintenance plus physician training contracts. Critically, Bebig's low-dose brachytherapy treatment has been included in the Russian state High-Tech Medical Care (VMP) program, meaning treatments using the technology are government-funded for Russian citizens. Named partners and customers are concentrated in Russian state and academic oncology institutions (Blokhin NMIC, NMIC Radiology, Hospital No. 122, Sevastopol Oncology Center, Tyumen State Medical University), with one international reference site in Bratislava, Slovakia. The company is ISO 13485:2016 certified and reports no public listing, ticker, or institutional investor disclosures.

Bebig firmographics

Firmographics
Name
Bebig
Legal name
ООО «БЕБИГ»
Website
https://bebig.ru
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Bebig is a Russian medical technology company that manufactures radioactive sources and brachytherapy systems—including I-125 prostate microseeds, Y-90 liver microspheres, high-dose Co-60/Ir-192 delivery systems, and related planning software—sold to state oncology hospitals and cancer centers, with treatments partially covered by Russian state High-Tech Medical Care programs.
Ownership category
akta.pro rank

Bebig industry classification

Industry
Product category
Radiation Oncology and Brachytherapy Systems
NAICS
Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)
SIC
X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAKAFAC
Radiation Oncology
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Brachytherapy medical devices
  • Radiation oncology systems
  • Prostate cancer treatment
  • Liver cancer radioembolization
  • Medical isotope products

Where Bebig is headquartered

Location

Headquarters

HQ city
Moscow
HQ country
Russia
HQ region
Europe

Offices1 record

Markets served

Bebig business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Medical devices and equipment: Sale and service of brachytherapy equipment including Multisource and SagiNova high-dose therapy systems, planning software (SagiPlan), and Womed intraoperative radiation therapy devices
  2. Consumables and microseeds: I-125 microseeds for low-dose brachytherapy, Y-90 microspheres for liver cancer treatment, and Ru-106 ophthalmological applicators
  3. Service and training: Service maintenance for therapy equipment, physician training programs in Russia and abroad, and organization of brachytherapy treatment rooms in clinics

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Bebig product offering

Product offering

Core offering

Bebig develops, manufactures, and supplies brachytherapy and radiation oncology products for cancer treatment. The portfolio includes I-125 low-dose microseeds for prostate cancer brachytherapy, Y-90 microspheres for liver cancer radioembolization, Multisource and SagiNova high-dose brachytherapy systems using Co-60 and Ir-192 isotopes, SagiPlan dosimetry software, MRI/ultrasound fusion biopsy systems, Ru-106 ophthalmic applicators, Womed intraoperative radiation therapy devices, and Biobeam blood irradiation systems, complemented by service maintenance, physician training, and brachytherapy room organization services.

Product overview

Bebig is a Russian medical technology company specializing in advanced brachytherapy and radiation oncology products. The company's portfolio includes low-dose rate brachytherapy micro-sources (I-125) for prostate cancer treatment, Y-90 microspheres for radioembolization of liver tumors, high-dose rate brachytherapy systems (Multisource, SagiNova, SagiPlan) using Co-60 and Ir-192 isotopes, fusion biopsy systems for prostate cancer diagnosis, Ru-106 ophthalmic applicators, Womed devices for intraoperative radiation therapy, and Biobeam blood irradiation systems. The company operates as a unified product portfolio focused on nuclear medicine and radiation oncology solutions for cancer treatment across multiple treatment areas including prostate cancer, liver cancer, and eye tumors.

Differentiator

Problem solved

Functional benefit

Brands

  • SagiNova: High-dose brachytherapy system for remote introduction of high-dose radioactive preparations
  • SagiPlan
  • Multisource
  • Biobeam
  • Womed

Products and services

  • I-125 Microseeds for Low-Dose Brachytherapy

Quantifiable outcome

  • 10-year survival rate averages 87% according to various studies
  • +2 more outcomes

Companies that use Bebig

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Bebig technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bebig partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • Sevastopol Oncology CenterminorStrategic or Co-development Partner · 5 May 2026Recently began performing radioembolization of liver tumors using Bebig-produced Y-90 microspheres as of May 2026.
  • FSBI NMITs Oncology named after N.N. Blokhin of the Ministry of Health of RussiacoreStrategic or Co-development PartnerMajor national oncology center collaborating with Bebig on brachytherapy treatments. The center's deputy director for development of oncological care in regions serves as an expert advocate for brachytherapy as an innovative method combining advanced technologies with excellent results and minimally invasive techniques.
  • FSBI NMIC Radiology of the Ministry of Health of RussiacoreStrategic or Co-development PartnerLeading national radiology center under the Ministry of Health, headed by the Chief внештатный oncologist of Russia. The center collaborates with Bebig as an example of quality and reliable import substitution, particularly in radiofarm production with Russian Y-90 microspheres.
  • FMBU Clinical Hospital No. 122 named after L.G. SokolovcoreStrategic or Co-development PartnerLeading brachytherapy center performing prostate cancer treatments. The hospital's Prostate Cancer Brachytherapy Center, led by a Prize laureate of the St. Petersburg Government, uses Bebig technology exclusively.
  • Tyumen State Medical University Oncology DepartmentminorStrategic or Co-development PartnerAcademic institution conducting research on brachytherapy effectiveness, with studies reporting 87% 10-year survival rates.
  • Saint Elizabeth Oncology Institute (Bratislava, Slovakia)minorStrategic or Co-development PartnerInternational reference center using Bebig technology, with published studies confirming brachytherapy effectiveness for prostate cancer across risk groups.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Bebig competitors and assessment

Company assessment

Direct peers

  • Boston Scientific (TheraSphere): Boston Scientific's TheraSphere Y-90 glass microspheres compete head-to-head with Bebig's Y-90 product for liver cancer radioembolization procedures across major cancer centers.
  • Varian (Siemens Healthineers): Varian offers the GammaMed, VariSource, and Bravos HDR brachytherapy afterloaders and the BrachyVision planning system, directly competing with Bebig's high-dose brachytherapy portfolio in hospitals globally.
  • IsoRay Medical: IsoRay manufactures Cesium-131 and I-125 brachytherapy seeds for prostate and other cancers - directly comparable isotope-based seed product category to Bebig's I-125 microseeds.
  • Nordion (Sotera Health): Nordion supplies medical isotopes including Co-60 and I-125 used in brachytherapy devices and sterilization - a key input supplier and indirect competitor to Bebig's vertically integrated isotope production.
  • Theragenics: Theragenics produces brachytherapy seeds (I-125, Pd-103) and operates the Galt Medical and surgical products businesses, overlapping directly with Bebig's brachytherapy seed and applicator portfolio.
  • Eckert & Ziegler (BEBIG GmbH): Eckert & Ziegler acquired the original German BEBIG and produces HDR brachytherapy afterloaders (Multisource, SagiNova) and I-125 seeds that Bebig (Russia) distributes alongside its own microsphere production. Directly comparable product portfolio and isotope-based technology.
  • Sirtex Medical: Sirtex manufactures SIR-Spheres Y-90 resin microspheres for liver radioembolization - the global benchmark for the product that Bebig is producing domestically in Russia. Closest direct competitor in the Y-90 microsphere category.
  • Elekta: Elekta is the global leader in HDR brachytherapy afterloaders (Flexitron), treatment planning software, and applicators - directly competing with Bebig's Multisource/SagiNova systems and SagiPlan planning software in radiation oncology.

Regional players

  • BEBIG Medical (China): The Chinese BEBIG Medical entity sells Eckert & Ziegler-derived brachytherapy products (HDR afterloaders, seeds) into the Chinese and Asian markets - same product lineage as the systems Bebig (Russia) distributes, but serving a different geography without direct overlap.

Emerging players

  • Mevion Medical Systems: Mevion develops compact proton therapy systems as an alternative radiation oncology modality; not a direct brachytherapy peer but competes for radiation oncology capital budgets at the same hospitals Bebig sells into.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Bebig social profiles

Digital presence

Bebig compliance and trust

Trust signal

Compliance1 record

Bebig financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bebig leadership team

Management profile

Number of profiles

Bebig funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bebig M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bebig

What does Bebig do?

Bebig develops, manufactures, and supplies brachytherapy and radiation oncology products for cancer treatment. The portfolio includes I-125 low-dose microseeds for prostate cancer brachytherapy, Y-90 microspheres for liver cancer radioembolization, Multisource and SagiNova high-dose brachytherapy systems using Co-60 and Ir-192 isotopes, SagiPlan dosimetry software, MRI/ultrasound fusion biopsy systems, Ru-106 ophthalmic applicators, Womed intraoperative radiation therapy devices, and Biobeam blood irradiation systems, complemented by service maintenance, physician training, and brachytherapy room organization services.

Is Bebig a public or private company?

Bebig is a private company. It is classified as venture growth investor backed and is currently operating.

When was Bebig founded?

Bebig was founded in 2015. It employs 11 to 50 people.

Where is Bebig based?

Bebig is headquartered in Moscow, Russia, in the Europe region.

How does Bebig make money?

Three revenue lines are on record. Medical devices and equipment is the primary driver. The others are consumables and microseeds and service and training.

Who are Bebig's main competitors?

Direct peers on record are Boston Scientific (TheraSphere), Varian (Siemens Healthineers), IsoRay Medical, Nordion (Sotera Health), Theragenics, Eckert & Ziegler (BEBIG GmbH), Sirtex Medical and Elekta. BEBIG Medical (China) is listed as a regional player. Mevion Medical Systems is listed as an emerging player.

Does Bebig have an API?

No public API is recorded for Bebig.

What industry is Bebig in?

Bebig's product category is Radiation Oncology and Brachytherapy Systems. Its primary akta.pro industry code is EUAKAIAD, Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals